Generis Knowledge Management Announces that Otsuka Pharmaceutical selected its CARA product suite as an Electronic Document Management System globally
Generis Knowledge Management, Inc. announced today that Otsuka Pharmaceutical has selected CARA as their next generation electronic document management system for regulatory content management in support of new pharmaceutical applications submitted to the health authorities worldwide.
CARA will be implemented at Otsuka and accessed globally by users in Japan, rest of Asia, the U.S., Canada and Europe, as well as its affiliates Taiho Pharmaceutical, Taiho Oncology, Astex Pharmaceuticals, and Avanir Pharmaceuticals.
“We are very pleased to award Otsuka’s next generation of global electronic management system to Generis. The selection was the outcome of a detailed product evaluation, which included many well-known and emerging companies. We found CARA the best product to meet our global business needs and multi-language requirements. Their companies’ leadership and team were knowledgeable and responsive throughout the process, and they were very cost competitive. Overall, CARA is a highly configurable product suite that offers improved user interface, better overall system performance, abilities to interface with other internal systems, and capabilities that exceed expectations for our mobile business needs” said Kenji Nagamura, a senior member and sponsor of the product evaluation team at Otsuka.
“We are very excited to have been selected by Otsuka and its affiliates for such a business-critical system.” said James Kelleher, CEO at Generis. “Otsuka is an industry leader in Japan, and the project itself will be an opportunity for users across the globe to work in a single harmonized platform, while protecting the security and confidentiality of the documents of each company within the group. We expect Otsuka to be able to recognize considerable usability improvements and efficiencies.”
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: “Otsuka – people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka Pharmaceutical Co., Ltd. is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan.
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka Pharmaceutical at www.otsuka.co.jp/en/.